

Using genetically modified stem cells to halt the progression of ALS

Francisco D. Benavides, MD;¹ Teresa A. Evans, BS, BA;² Todd E. White, PhD;³ Zijia Zhang, BS⁴

¹The Miami Project, University of Miami, Miami, FL; ²Department of Neuroscience, Case Western Reserve University, Cleveland, OH; ³Department of Neurobiology, Morehouse School of Medicine, Atlanta, GA; ⁴Department of Anatomy and Cell Biology, Oklahoma State University, Tulsa, OK

Abstract—The following was completed as part of the 2011 Route 28 Summit at the International Symposium on Neural Regeneration. The topic of the Route 28 Summit was, “Novel Ways to Exploit Stem Cells for Recovery of Central Human Nervous System Function.” Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease characterized by the loss of motor neurons leading to paralysis and death. The vast majority of ALS cases are idiopathic; however, at least 2% are caused by mutation of the copper-zinc superoxide dismutase 1 gene on chromosome 21. Here, we propose a three-pronged approach: (1) identify the molecular trigger for the onset of symptomatic ALS using a microarray approach, (2) develop a genetically modified cell-based treatment, and (3) restore lost respiratory function once disease progression has been halted by an implanted stem cell treatment.

BACKGROUND AND SIGNIFICANCE

ALS is a neurodegenerative disease affecting about 30,000 Americans [1]. The typical timecourse of the disease from onset to death is two to five years. Most cases of ALS are idiopathic and the precipitating factor in genetic cases is yet unknown. Currently, the only approved clinical treatment is Riluzole, which blocks glutamatergic transmission in the CNS [2]. Clinical trials have been conducted with varied success using modified stem cells [3–4], anti-glutamatergic factors [5–7], and neurotrophic factors [8]. Further investigation is needed to determine the cause and molecular triggers of the ALS, and the development of an effective treatment. First, we propose an extensive microarray study using induced pluripotent stem cells (iPSCs) derived from patients with ALS-SOD1 to determine what molecular change occurs at the onset of symptomatic ALS. Second, we propose a novel intervention/therapy using genetically modified autologous hematopoietic stem cells. Finally, we present a simple method for restoring respiratory function in patients using stem cells to form interneuronal relays.

PROPOSED STUDY AND METHODS

Hypothesis Statement

We hypothesize that stem cells can be modified to deliver protective factors to the CNS in order to halt the progression of ALS.

Aim 1: To Determine the Molecular Trigger For Motor Neuron Death And Symptom

Presentation in ALS-SOD1 Patients

We will use gene microarray technology to investigate the gene expression profiles of cells from ALS-SOD1 patients before and after onset of symptoms, and cells from healthy subjects (controls). Fibroblasts will be harvested from ALS-SOD1 patients ($n = 20$) and age matched controls ($n = 5$) every four months over the five year period during which symptomatic onset typically occurs. The fibroblasts will be transformed into iPSCs which will be induced to become motor neurons, oligodendrocytes, astrocytes, microglia and macrophages [9–12]. Since the initiating trigger for ALS is not known, all of these cell types need to be investigated. Mixed cell cultures of all possible combinations of ALS-SOD1 and control cells will be grown. mRNA will be isolated from each culture condition, hybridized to the Affymetrix GeneChip Human Genome U133 Plus 2.0 array for microarray analysis, and fold changes will be calculated. The resulting gene data sets will be further analyzed with Ingenuity Pathway Analysis (IPA, Ingenuity Systems, Inc.) for comparison analysis. Gene expression patterns that correlate with disease progression and cell type will be identified. For this exercise, we hypothesize that we will find transcription regulators that correlate with symptomatic progression. Based on current literature, we propose that these transcription factors will include c-Fos and JunD because the expression levels increase dramatically at the time symptoms are observed [13]. Identifying these molecular triggers will allow for therapeutic interventions that target these molecules and their related signaling pathways.

Aim 2: To Develop Hematopoietic Derived Monocytes Modified to be Protective Against ALS

While Retaining the Innate Ability to Home to Lesioned Areas

In order to deliver therapeutic factors to the sites of neuronal loss in ALS, macrophages derived from autologous bone marrow derived hematopoietic cells by standard protocols [14] will be used to

home to areas of inflammation by endogenous mechanisms. Similar cell types have been shown to home to areas of inflammation in myocardial infarction and glomerular nephritis [15–16]. These cells will then be infected with multiple replication incompetent lentiviral expression vectors to drive the cells toward a wound healing macrophage phenotype, alleviate the damage caused by ALS, and allow for elimination of these cells at later times. Cell lines will then be generated that stably express these factors. Gene expression in all viral vectors will be driven by the MMP-9 promoter.

As presented in the **Figure**, IL4 and IL13 will be used to drive monocytes into an M2 type macrophage phenotype with wound healing properties [17]. To alleviate damage caused by ALS, insulin-like growth factor-1 (IGF-1), somatostatin, c-Jun N-terminal kinase inhibitor (D-JNK-1) and excitatory amino-acid transporter 2 (EAAT2) will be expressed. IGF-1 promotes cellular proliferation, cellular differentiation and inhibition of apoptosis when activated. Although unsuccessful in clinical trials when delivered by subcutaneous injection [18], IGF-1 was shown to exert neuroprotective effects in a mouse model of ALS when delivered by lenti-viral vector [19], and has also shown increases in mesenchymal stem cell engraftment when expressed by transplanted cells [15]. Somatostatin and D-JNKI-1 inhibit c-Fos and JunD, respectively, and, turn off the trigger of ALS that we (hypothetically) derived from our microarray studies [13,20–22]. EAAT2, which increases glutamate re-uptake at the synaptic cleft, will reduce the excitotoxic effect of glutamate in ALS [5,23–24]. Herpes simplex virus-thymidine kinase (HSV-TK) generates monocyte susceptibility to Ganciclovir [25], allowing removal of any excess cells.




Figure. Proposed genetic modifications of hematopoietic derived monocytes.

We will transfer these modified monocytes into a SOD1-G93A mouse model of ALS using an established femoral vein systemic delivery technique [26]. After transplantation, animals will be monitored. Once symptoms have diminished or stabilized, animals will undergo a blood-brain barrier (BBB) integrity test using IV injection of biotin conjugated dextran [27]. At the point where the dextran is no longer found outside of the blood vessels in sectioned tissue, we will administer Ganciclovir conjugated to a high molecular weight dextran to prevent travel across the BBB and restrict HSV-TK mediated cell death to areas outside of the CNS. In order to prevent excess cell death due to the bystander effect, we will administer dexamethasone concomitantly [28].

Aim 3: To Augment Respiratory Function in a Rodent Model of ALS Once Disease Progression is Halted by Our Treatment Protocol

We will use the SOD1-G93A rat model to test whether autologous bone marrow derived

hematopoietic cells driven to become neural precursor cells (NPCs) [29–30] can promote improved respiratory behavior. NPCs will be stereotactically transplanted in the cervical spinal cord at the level of the phrenic motor nucleus of the transgenic rats. Several segmental injections will be used to deliver cells and populate the area around the phrenic motor neuron pool. NPCs transplanted in similar fashion have been shown to develop into interneuronal phenotypes that become integrated into the phrenic motor pathway and alter respiratory patterns [31–32]. Baseline plethysmographic and electrophysiological parameters will be evaluated and compared to post-transplant time points.

DISCUSSION AND CONCLUSIONS

This proposal describes an innovative approach to understanding and treating ALS. Three challenges are addressed: identification of a precipitating factor in development of ALS symptoms, application of a systemic treatment that will be able to reach the entire CNS in a biologically relevant way, and treatment of the devastating loss of respiratory function seen in late stages of the disease. However, this approach is currently technically unfeasible. First, discovery of the molecular trigger for ALS would require approximately 285,000 microarray chips to analyze all the mixed cell cultures proposed. Such an undertaking would be very expensive and require an enormous amount of labor for tissue processing and data analysis. Allowed unlimited resources, as we were in this exercise, we were freed from this limitation. Second, it is doubtful that a single cell could be stably transfected with as many genes as we have proposed and secrete all these factors at clinically relevant levels. However, this could be approximated with several genetically modified cells being co-transplanted. Transplantation of NPCs to augment respiratory function is feasible but would be insufficient for treating ALS without a treatment to halt or slow the progression of the disease. The idea that transcription factors are the key molecules for the progression of neurodegenerative diseases is being pursued [33] and, therefore, may yet prove to be part of the molecular trigger for symptomatic ALS. Focusing on the factors that lead to progression of the disease instead of the causative factors has the potential to extend the application of these results beyond the SOD1 form of ALS to the idiopathic cases as well.

REFERENCES

1. ALS Association [Internet]. Facts you should know. Washington (DC): The ALS Association; 2010. Available from: <http://www.alsa.org/about-als/facts-you-should-know.html>
2. Doble A. The pharmacology and mechanism of action of riluzole. *Neurology*. 1996;47(6, Suppl 4):S233–41. [PMID:8959995] http://dx.doi.org/10.1212/WNL.47.6_Suppl_4.233S
3. Martínez HR, Molina-Lopez JF, Alez-Garza MT, Moreno-Cuevas JE, Caro-Osorio E, Gil-Valadez A, Gutierrez-Jimenez E, Zazueta-Fierro OE, Meza JA, Couret-Alcaraz P, Hernandez-Torre M. Stem cell transplantation in amyotrophic lateral sclerosis patients. Methodological approach, safety, and feasibility. *Cell Transplant*. Epub 2012 Feb 13. [PMID:22329998]
4. Mazzini L, Fagioli F, Boccaletti R, Mareschi K, Oliveri G, Olivieri C, Pastore I, Marasso R, Madon E. Stem cell therapy in amyotrophic lateral sclerosis: a methodological approach in humans. *Amyotroph Lateral Scler Other Motor Neuron Disord*. 2003;4(3):158–61. [PMID:13129802] <http://dx.doi.org/10.1080/14660820310014653>
5. Kim K, Lee SG, Kegelman TP, Su ZZ, Das SK, Dash R, Dasgupta S, Barral PM, Hedvat M, Diaz P, Reed JC, Stebbins JL, Pellecchia M, Sarkar D, Fisher PB. Role of excitatory amino acid transporter-2 (EAAT2) and glutamate in neurodegeneration: opportunities for developing novel therapeutics. *J Cell Physiol*. 2011;226(10):2484–93. [PMID:21792905] <http://dx.doi.org/10.1002/jcp.22609>
6. Miller RG, Mitchell JD, Lyon M, Moore DH. Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND). *Amyotroph Lateral Scler Other Motor Neuron Disord*. 2003;4(3):191–206. [PMID:13129806] <http://dx.doi.org/10.1080/14660820310002601>
7. Miller RG, Mitchell JD, Lyon M, Moore DH. Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND). *Cochrane Database Syst Rev*. 2012;3:CD001447. [PMID:22419278] <http://dx.doi.org/10.1002/14651858.CD001447.pub3>
8. Saccà F, Quarantelli M, Rinaldi C, Tucci T, Piro R, Perrotta G, Carotenuto B, Marsili A, Palma V, De Michele G, Brunetti A, Brescia Morra V, Filla A, Salvatore M. A randomized controlled clinical trial of growth hormone in amyotrophic lateral sclerosis: clinical, neuroimaging, and hormonal results. *J Neurol*. 2012;259(1):132–38. [PMID:21706151] <http://dx.doi.org/10.1007/s00415-011-6146-2>

9. Amabile G, Meissner A. Induced pluripotent stem cells: current progress and potential for regenerative medicine. *Trends Mol Med.* 2009;15(2):59–68. [\[PMID:19162546\]](#)
<http://dx.doi.org/10.1016/j.molmed.2008.12.003>
10. Takahashi K, Tanabe K, Ohnuki M, Narita M, Ichisaka T, Tomoda K, Yamanaka S. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. *Cell.* 2007;131(5):861–72.
[\[PMID:18035408\]](#) <http://dx.doi.org/10.1016/j.cell.2007.11.019>
11. Wernig M, Meissner A, Foreman R, Brambrink T, Ku M, Hochedlinger K, Bernstein BE, Jaenisch R. In vitro reprogramming of fibroblasts into a pluripotent ES-cell-like state. *Nature.* 2007;448(7151):318–24. [\[PMID:17554336\]](#) <http://dx.doi.org/10.1038/nature05944>
12. Ogawa S, Tokumoto Y, Miyake J, Nagamune T. Induction of oligodendrocyte differentiation from adult human fibroblast-derived induced pluripotent stem cells. *In Vitro Cell Dev Biol Anim.* 2011;47(7):464–69. [\[PMID:21695581\]](#) <http://dx.doi.org/10.1007/s11626-011-9435-2>
13. Yoshihara T, Ishigaki S, Yamamoto M, Liang Y, Niwa J, Takeuchi H, Doyu M, Sobue G. Differential expression of inflammation- and apoptosis-related genes in spinal cords of a mutant SOD1 transgenic mouse model of familial amyotrophic lateral sclerosis. *J Neurochem.* 2002;80(1):158–67.
[\[PMID:11796754\]](#) <http://dx.doi.org/10.1046/j.0022-3042.2001.00683.x>
14. Ishikawa K, Yoshida S, Nakao S, Sassa Y, Asato R, Kohno R, Arima M, Kita T, Yoshida A, Ohuchida K, Ishibashi T. Bone marrow-derived monocyte lineage cells recruited by MIP-1beta promote physiological revascularization in mouse model of oxygen-induced retinopathy. *Lab Invest.* 2012;92(1):91–101. [\[PMID:21912378\]](#) <http://dx.doi.org/10.1038/labinvest.2011.141>
15. Haider HK, Jiang S, Idris NM, Ashraf M. IGF-1-overexpressing mesenchymal stem cells accelerate bone marrow stem cell mobilization via paracrine activation of SDF-1alpha/CXCR4 signaling to promote myocardial repair. *Circ Res.* 2008;103(11):1300–8. [\[PMID:18948617\]](#)
<http://dx.doi.org/10.1161/CIRCRESAHA.108.186742>
16. Wilson HM, Stewart KN, Brown PA, Anegon I, Chettibi S, Rees AJ, Kluth DC. Bone-marrow-derived macrophages genetically modified to produce IL-10 reduce injury in experimental

glomerulonephritis. *Mol Ther.* 2002;6(6):710–17. [\[PMID:12498767\]](#)

<http://dx.doi.org/10.1006/mthe.2002.0802>

17. Martinez FO, Helming L, Gordon S. Alternative activation of macrophages: an immunologic functional perspective. *Annu Rev Immunol.* 2009;27:451–83. [\[PMID:19105661\]](#)

<http://dx.doi.org/10.1146/annurev.immunol.021908.132532>

18. Sorenson EJ, Windbank AJ, Mandrekar JN, Bamlet WR, Appel SH, Armon C, Barkhaus PE, Bosch P, Boylan K, David WS, Feldman E, Glass J, Gutmann L, Katz J, King W, Luciano CA, McCluskey LF, Nash S, Newman DS, Pascuzzi RM, Pioro E, Sams LJ, Scelsa S, Simpson EP, Subramony SH, Tiryaki E, Thornton CA. Subcutaneous IGF-1 is not beneficial in 2-year ALS trial. *Neurology.* 2008;71(22):1770–75. [\[PMID:19029516\]](#) <http://dx.doi.org/10.1212/01.wnl.0000335970.78664.36>

19. Kaspar BK, Lladó J, Sherkat N, Rothstein JD, Gage FH. Retrograde viral delivery of IGF-1 prolongs survival in a mouse ALS model. *Science.* 2003;301(5634):839–42. [\[PMID:12907804\]](#)

<http://dx.doi.org/10.1126/science.1086137>

20. Todisco A, Campbell V, Dickinson CJ, DelValle J, Yamada T. Molecular basis for somatostatin action: inhibition of c-fos expression and AP-1 binding. *Am J Physiol.* 1994;267(2 Pt 1):G245–53.

[\[PMID:7915496\]](#)

21. Hirt L, Badaut J, Thevenet J, Granziera C, Regli L, Maurer F, Bonny C, Bogousslavsky J. D-JNK11, a cell-penetrating c-Jun-N-terminal kinase inhibitor, protects against cell death in severe cerebral ischemia. *Stroke.* 2004;35(7):1738–43. [\[PMID:15178829\]](#) <http://dx.doi.org/10.1161/01.STR.0000131480.03994.b1>

22. Hasel C, Dürr S, Bauer A, Heydrich R, Brüderlein S, Tambi T, Bhanot U, Möller P. Pathologically elevated cyclic hydrostatic pressure induces CD95-mediated apoptotic cell death in vascular endothelial cells. *Am J Physiol Cell Physiol.* 2005;289(2):C312–22. [\[PMID:15772124\]](#)

<http://dx.doi.org/10.1152/ajpcell.00107.2004>

23. Gras G, Porcheray F, Samah B, Leone C. The glutamate-glutamine cycle as an inducible, protective face of macrophage activation. *J Leukoc Biol.* 2006;80(5):1067–75. [\[PMID:16912070\]](#)

<http://dx.doi.org/10.1189/jlb.0306153>

24. Liang H, Ward WF, Jang YC, Bhattacharya A, Bokov AF, Li Y, Jernigan A, Richardson A, Van Remmen H. PGC-1 α protects neurons and alters disease progression in an amyotrophic lateral sclerosis mouse model. *Muscle Nerve*. 2011;44(6):947–56. [PMID:22102466]
<http://dx.doi.org/10.1002/mus.22217>
25. Berger C, Flowers ME, Warren EH, Riddell SR. Analysis of transgene-specific immune responses that limit the in vivo persistence of adoptively transferred HSV-TK-modified donor T cells after allogeneic hematopoietic cell transplantation. *Blood*. 2006;107(6):2294–2302. [PMID:16282341]
<http://dx.doi.org/10.1182/blood-2005-08-3503>
26. Paul C, Samdani AF, Betz RR, Fischer I, Neuhuber B. Grafting of human bone marrow stromal cells into spinal cord injury: a comparison of delivery methods. *Spine*. 2009;34(4):328–34. [PMID:19182705]
<http://dx.doi.org/10.1097/BRS.0b013e31819403ce>
27. DiNapoli VA, Huber JD, Houser K, Li X, Rosen CL. Early disruptions of the blood-brain barrier may contribute to exacerbated neuronal damage and prolonged functional recovery following stroke in aged rats. *Neurobiol Aging*. 2008;29(5):753–64. [PMID:17241702]
<http://dx.doi.org/10.1016/j.neurobiolaging.2006.12.007>
28. Robe PA, Nguyen-Khac M, Jolais O, Rogister B, Merville MP, Bours V. Dexamethasone inhibits the HSV-tk/ ganciclovir bystander effect in malignant glioma cells. *BMC Cancer*. 2005;5:32.
[PMID:15804364] <http://dx.doi.org/10.1186/1471-2407-5-32>
29. Lepore AC. Intraspinal cell transplantation for targeting cervical ventral horn in amyotrophic lateral sclerosis and traumatic spinal cord injury. *J Vis Exp*. 2011;(55):ii. [PMID:21946609]
<http://dx.doi.org/10.3791/3069>
30. Silani V, Cova L, Corbo M, Ciammola A, Polli E. Stem-cell therapy for amyotrophic lateral sclerosis. *Lancet*. 2004;364(9429):200–202. [PMID:15246734] [http://dx.doi.org/10.1016/S0140-6736\(04\)16634-8](http://dx.doi.org/10.1016/S0140-6736(04)16634-8)
31. White TE, Lane MA, Sandhu MS, O'Steen BE, Fuller DD, Reier PJ. Neuronal progenitor transplantation and respiratory outcomes following upper cervical spinal cord injury in adult rats. *Exp Neurol*. 2010;225(1):231–36. [PMID:20599981] <http://dx.doi.org/10.1016/j.expneurol.2010.06.006>

32. Lane MA, White TE, Coutts MA, Jones AL, Sandhu MS, Bloom DC, Bolser DC, Yates BJ, Fuller DD, Reier PJ. Cervical prephrenic interneurons in the normal and lesioned spinal cord of the adult rat. *J Comp Neurol*. 2008;511(5):692–709. [\[PMID:18924146\]](#) <http://dx.doi.org/10.1002/cne.21864>
33. Kane MJ, Citron BA. Transcription factors as therapeutic targets in CNS disorders. *Recent Pat CNS Drug Discov*. 2009;4(3):190–99. [\[PMID:19891598\]](#)